SANTIAGO — Sinovac’s Coronavirus Disease 2019 (COVID-19) vaccine was 58.5% effective in preventing the symptomatic disease of millions of Chileans received between February and July, while Pfizer’s COVID -19 shots were 87.7% valid. AstraZeneca was 68.7% effective.
The data are included in the latest “real world” data published by the Chilean authorities on the effectiveness of the COVID-19 vaccine in the raft population.
Chile launched one of the world’s fastest vaccination campaigns for COVID-19 in December and now fully vaccinates more than 60% of its population, primarily Sinovac’s CoronaVac.
Health official Dr. Rafael Araos said at a press conference on Tuesday that the vaccine was 86% effective in preventing hospitalizations, 89.7% in preventing hospitalizations in the intensive care unit, and 86% in preventing population deaths. Stated.
In April, the same study found that CoronaVac was 67% effective in preventing symptomatological disorders, 85% in preventing hospitalizations, and 80% in preventing deaths. This suggests that while the ability to prevent the more serious effects of the virus has been strengthened, that ability has been strengthened. Decreased to stop symptomatic illness.
Dr. Araos said that reduced protection from vaccines is unavoidable over time, especially due to the arrival and spread of more toxic strains such as delta mutants.
“As Delta becomes more prevalent and the vaccine becomes less responsive, faster drops may be observed. [in effectiveness]”He said, adding his voice, demanding that a third booster dose be issued.
The government also released data on the efficacy of other vaccines administered in Chile, produced by Pfizer BioNTech and AstraZeneca.
At the same time, Pfizer’s vaccine was 87.7% effective in preventing symptomatic COVID-19, 98% in preventing hospitalization in the intensive care unit, and 100% effective in preventing death, Dr. Araos said.
At the same time, AstraZeneca was 68.7% effective in preventing symptomatological COVID-19, 98% in preventing hospitalization in the intensive care unit, and 100% effective in preventing death, Dr. Araos said.
A Chilean study examined the effectiveness of the vaccine among different cohorts of people who were vaccinated twice, partially vaccinated, or never vaccinated.
The CoronaVac part of the survey surveyed a group of 8.6 million people, the Pfizer BioNTech part surveyed a group of 4.5 million people, and the AstraZeneca part surveyed a group of 2.3 million people. — — Aislinn Laing When Fabian Cambello / Reuters
Chilean studies show a variation on the success of the COVID-19 vaccine
https://www.bworldonline.com/chilean-study-shows-variations-in-success-of-covid-19-vaccines/ Chilean studies show a variation on the success of the COVID-19 vaccine